Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

What’s New With Measuring Cholesterol?

What’s New With Measuring Cholesterol? Opinion Editorials represent the opinions of the authors and JAMA EDITORIAL and not those of the American Medical Association. J. Michael Gaziano, MD, MPH; Thomas A. Gaziano, MD, MSC Exactly 100 years ago, one of the most important lines of smoking, were key risk factors prospectively related to risk research in cardiology began—the story of cholesterol. This of coronary heart disease. Total cholesterol and, later, low- complicated saga has many twists and turns and much con- density lipoprotein cholesterol (LDL-C) and high-density troversy, even continuing to today. It is the tale of a simple lipoprotein cholesterol (HDL-C), figure prominently into the compound that has been the subject of thousands of papers Framingham risk score. and several Nobel prizes. Every type of researcher from Generations of trialists honed their skills developing ran- chemists to basic scientists to epidemiologists to trialists to domized clinical trials to test the cholesterol hypothesis with health services researchers and health economists has lipid-lowering strategies. The early dietary trials gave way to played an important role in the progression of this drama. the early lipid-lowering drugs, and small trials gave way to Billions of dollars have been invested in developing and large-scale mega trials. Early medications http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

What’s New With Measuring Cholesterol?

JAMA , Volume 310 (19) – Nov 20, 2013

Loading next page...
 
/lp/american-medical-association/what-s-new-with-measuring-cholesterol-zhE9JyxbT4
Publisher
American Medical Association
Copyright
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2013.282775
pmid
24240929
Publisher site
See Article on Publisher Site

Abstract

Opinion Editorials represent the opinions of the authors and JAMA EDITORIAL and not those of the American Medical Association. J. Michael Gaziano, MD, MPH; Thomas A. Gaziano, MD, MSC Exactly 100 years ago, one of the most important lines of smoking, were key risk factors prospectively related to risk research in cardiology began—the story of cholesterol. This of coronary heart disease. Total cholesterol and, later, low- complicated saga has many twists and turns and much con- density lipoprotein cholesterol (LDL-C) and high-density troversy, even continuing to today. It is the tale of a simple lipoprotein cholesterol (HDL-C), figure prominently into the compound that has been the subject of thousands of papers Framingham risk score. and several Nobel prizes. Every type of researcher from Generations of trialists honed their skills developing ran- chemists to basic scientists to epidemiologists to trialists to domized clinical trials to test the cholesterol hypothesis with health services researchers and health economists has lipid-lowering strategies. The early dietary trials gave way to played an important role in the progression of this drama. the early lipid-lowering drugs, and small trials gave way to Billions of dollars have been invested in developing and large-scale mega trials. Early medications

Journal

JAMAAmerican Medical Association

Published: Nov 20, 2013

References